{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:56:18Z","timestamp":1790484978501,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MITIGATE project, co-founded by the European Community's 7th Framework Programme"},{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB is a novel DOTA-coupled Gastrin Releasing Peptide Receptor (GRPR) antagonist with high affinity for GRPR and good in vivo stability. This study aimed at (1) the translation of preclinical results to the clinics and establish the preparation of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB using a GMP conform kit approach and a licensed\n                      <jats:sup>68<\/jats:sup>\n                      Ge\/\n                      <jats:sup>68<\/jats:sup>\n                      Ga generator and (2) to explore the application of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB in patients with gastrointestinal stromal tumors (GIST) before and\/or after interventional treatment (selective internal radiotherapy, irreversible electroporation, microwave ablation).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Validation of the production and quality control of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB for patient use had to be performed before starting the GMP production. Six independent batches of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB were produced, all met the quality and sterility criteria and yielded 712\u2009\u00b1\u200973\u2009MBq of the radiotracer in a radiochemical purity of &gt;\u200995% and a molar activity of 14.2\u2009\u00b1\u20091.5\u2009GBq\/\u03bcmol within 20\u2009min synthesis time and additional 20\u2009min quality control. Three patients (2 females, 1 male, 51\u201377\u2009yrs. of age) with progressive gastrointestinal stromal tumor metastases in the liver or peritoneum not responsive to standard tyrosine kinase inhibitor therapy underwent both [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB scans prior and after interventional therapy. Radiosynthesis of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NeoB was performed using a kit approach under GMP conditions. No specific patient preparation such as fasting or hydration was required for [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB PET\/CT imaging. Contrast-enhanced PET\/CT studies were performed. A delayed, second abdominal image after the administration of the of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB was acquired at 120\u2009min post injection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A fully GMP compliant kit preparation of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB enabling the routine production of the tracer under GMP conditions was established for clinical routine PET\/CT imaging of patients with metastatic GIST and proved to adequately visualize tumor deposits in the abdomen expressing GRPR. Patients could benefit from additional information derived from [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NeoB diagnosis to assess the presence of GRPR in the tumor tissue and monitor antitumor treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-021-00137-w","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T10:04:43Z","timestamp":1625565883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["GMP-compliant production of [68Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-5694","authenticated-orcid":false,"given":"Marc","family":"Pretze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Reffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"12","key":"137_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00117-009-1852-9","volume":"49","author":"G Antoch","year":"2009","unstructured":"Antoch G, Herrmann K, Heusner TA, Buck AK. Bildgebende Verfahren bei gastrointestinalen Stromatumoren. Radiologe. 2009;49(12):1109\u201316. https:\/\/doi.org\/10.1007\/s00117-009-1852-9.","journal-title":"Radiologe."},{"issue":"2","key":"137_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1021\/bc9701959","volume":"9","author":"KE Baidoo","year":"1998","unstructured":"Baidoo KE, Lin K-S, Zhan Y, Finley P, Scheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9(2):218\u201325. https:\/\/doi.org\/10.1021\/bc9701959.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"137_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnumed.119.234971","volume":"61","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, Maecke HR, Iagaru A. Imaging the distribution of gastrin releasing peptide receptors in Cancer. J Nucl Med. 2020;61(6):1\u201329. https:\/\/doi.org\/10.2967\/jnumed.119.234971.","journal-title":"J Nucl Med"},{"key":"137_CR4","doi-asserted-by":"publisher","unstructured":"Breeman WAP, de Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP. Pre-clinical evaluation of [111In-DTPA-Pro1,Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999;83:657\u2013663, Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy, 5, DOI: https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19991126)83:5<657::AID-IJC15>3.0.CO;2-Y.","DOI":"10.1002\/(SICI)1097-0215(19991126)83:5<657::AID-IJC15>3.0.CO;2-Y"},{"issue":"1","key":"137_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7150\/thno.13580","volume":"6","author":"KL Chatalic","year":"2016","unstructured":"Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, et al. In vivo stabilization of a Gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies. Theranostics. 2016a;6(1):104\u201317. https:\/\/doi.org\/10.7150\/thno.13580 Epub 2016\/01\/02. PubMed PMID: 26722377; PubMed Central PMCID: PMCPMC4679358.","journal-title":"Theranostics"},{"issue":"1","key":"137_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7150\/thno.13580","volume":"6","author":"KLS Chatalic","year":"2016","unstructured":"Chatalic KLS, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, et al. In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate Cancer in preclinical studies. Theranostics. 2016b;6(1):104\u201317. https:\/\/doi.org\/10.7150\/thno.13580.","journal-title":"Theranostics."},{"issue":"9","key":"137_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","volume":"18","author":"DB Cornelio","year":"2007","unstructured":"Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18(9):1457\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdm058 PubMed PMID: 17351255.","journal-title":"Ann Oncol"},{"issue":"8","key":"137_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2967\/jnumed.106.038091","volume":"48","author":"A Dimitrakopoulou-Strauss","year":"2007","unstructured":"Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, M\u00e4cke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med. 2007;48(8):1245\u201350. https:\/\/doi.org\/10.2967\/jnumed.106.038091 PubMed PMID: 17631559.","journal-title":"J Nucl Med"},{"issue":"7","key":"137_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, M\u00fcller M, Bauder-W\u00fcst U, Remde Y, Sch\u00e4fer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate Cancer. Pharmaceuticals. 2014;7(7):779\u201396. https:\/\/doi.org\/10.3390\/ph7070779 PubMed PMID: 24983957; PubMed Central PMCID: PMC4113732.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"137_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.4103\/0973-1482.177499","volume":"13","author":"A El-Menyar","year":"2017","unstructured":"El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: an up-to-date literature review. J Cancer Res Ther. 2017;13(6):889\u2013900. https:\/\/doi.org\/10.4103\/0973-1482.177499.","journal-title":"J Cancer Res Ther"},{"key":"137_CR11","unstructured":"GALLIUM (68Ga) EDOTREOTIDE INJECTION. PHARMEUROPA. 2011;23(2)."},{"issue":"1","key":"137_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41181-019-0086-z","volume":"5","author":"N Gillings","year":"2020","unstructured":"Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, et al. EANM guideline on the validation of analytical methods for radiopharmaceuticals. EJNMMI Radiopharm Chem. 2020;5(1):7. https:\/\/doi.org\/10.1186\/s41181-019-0086-z Epub 2020\/02\/14. ubMed PMID: 32052212; PubMed Central PMCID: PMCPMC7016057.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"137_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MED.0b013e3282f3709b","volume":"15","author":"N Gonzalez","year":"2008","unstructured":"Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15(1):58\u201364. https:\/\/doi.org\/10.1097\/MED.0b013e3282f3709b PubMed PMID: 18185064; PubMed Central PMCID: PMC2631407.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"137_CR14","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"L Gruber","year":"2020","unstructured":"Gruber L, Jimenez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, et al. MITIGATE-NeoBOMB1, a phase I\/IIa study to evaluate safety, pharmacokinetics and preliminary imaging of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients. J Nucl Med. 2020;61(12):1749\u201355. https:\/\/doi.org\/10.2967\/jnumed.119.238808. Epub 2020\/04\/26. PubMed PMID: 32332143.","journal-title":"J Nucl Med"},{"issue":"2","key":"137_CR15","first-page":"280","volume":"55","author":"G Halmos","year":"1995","unstructured":"Halmos G, Wittliff JL, Schally AV. Characterization of bombesin\/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55(2):280\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"137_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamaoncol.2016.5751","volume":"3","author":"H Joensuu","year":"2017","unstructured":"Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: An exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5751 Epub 2017\/03\/24. PubMed PMID: 28334365; PubMed Central PMCID: PMCPMC5470395.","journal-title":"JAMA Oncol"},{"issue":"1","key":"137_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/labinvest.3700360","volume":"86","author":"J Lasota","year":"2006","unstructured":"Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Investig. 2006;86(1):94\u2013100. https:\/\/doi.org\/10.1038\/labinvest.3700360 Epub 2005\/11\/01. PubMed PMID: 16258521.","journal-title":"Lab Investig"},{"issue":"1","key":"137_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1021\/acsomega.8b03293","volume":"4","author":"J Lau","year":"2019","unstructured":"Lau J, Rousseau E, Zhang Z, Uribe CF, Kuo HT, Zeisler J, et al. Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel Bombesin analogue. ACS omega. 2019;4(1):1470\u20138. https:\/\/doi.org\/10.1021\/acsomega.8b03293 PubMed PMID: 30775647; PubMed Central PMCID: PMC6372246.","journal-title":"ACS omega"},{"key":"137_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2147\/OTT.S31260","volume":"6","author":"M Linch","year":"2013","unstructured":"Linch M, Claus J, Benson C. Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther. 2013;6:1011\u201323. https:\/\/doi.org\/10.2147\/OTT.S31260.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"137_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1021\/bc4004662","volume":"25","author":"S Lindner","year":"2014","unstructured":"Lindner S, Michler C, W\u00e4ngler B, Bartenstein P, Fischer G, Schirrmacher R, et al. PESIN multimerization improves receptor avidities and in vivo tumor targeting properties to GRPR-overexpressing tumors. Bioconjug Chem. 2014;25(3):489\u2013500. https:\/\/doi.org\/10.1021\/bc4004662 Epub 2014\/02\/19. PubMed PMID: 24533789.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"137_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1021\/acs.jmedchem.7b01856","volume":"61","author":"C Liolios","year":"2018","unstructured":"Liolios C, Buchmuller B, Bauder-W\u00fcst U, Sch\u00e4fer M, Leotta K, Haberkorn U, et al. Monomeric and dimeric 68Ga-labeled bombesin analogues for positron emission tomography (PET) imaging of tumors expressing gastrin-releasing peptide receptors (GRPrs). J Med Chem. 2018;61(5):2062\u201374. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01856.","journal-title":"J Med Chem"},{"issue":"5","key":"137_CR22","first-page":"1152","volume":"59","author":"R Markwalder","year":"1999","unstructured":"Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59(5):1152\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"137_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.116.178889","volume":"58","author":"BA Nock","year":"2017","unstructured":"Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58(1):75\u201380. https:\/\/doi.org\/10.2967\/jnumed.116.178889 PubMed PMID: 27493272.","journal-title":"J Nucl Med"},{"key":"137_CR24","doi-asserted-by":"publisher","first-page":"105567","DOI":"10.1016\/j.biocel.2019.105567","volume":"114","author":"D Pooja","year":"2019","unstructured":"Pooja D, Gunukula A, Gupta N, Adams DJ, Kulhari H. Bombesin receptors as potential targets for anticancer drug delivery and imaging. Int J Biochem Cell Biol. 2019;114:105567. https:\/\/doi.org\/10.1016\/j.biocel.2019.105567 Epub 2019\/07\/12. PubMed PMID: 31295552.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"137_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1021\/acs.bioconjchem.8b00067","volume":"29","author":"M Pretze","year":"2018","unstructured":"Pretze M, Hien A, Radle M, Schirrmacher R, W\u00e4ngler C, W\u00e4ngler B. Gastrin-releasing peptide receptor- and prostate-specific membrane antigen-specific ultrasmall gold nanoparticles for characterization and diagnosis of prostate carcinoma via fluorescence imaging. Bioconjug Chem. 2018;29(5):1525\u201333. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00067 Epub 2018\/03\/16. PubMed PMID: 29542916.","journal-title":"Bioconjug Chem"},{"issue":"02","key":"137_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/a-1375-9605","volume":"44","author":"M Pretze","year":"2021","unstructured":"Pretze M, W\u00e4ngler C, Sch\u00f6nberg SO, W\u00e4ngler B. 68Ga-NeoB: preclinical results on imaging of gastrointestinal stromal tumors and determination of target receptor density in the gastrointestinal tract. Der Nuklearmediziner. 2021;44(02):102\u201312. https:\/\/doi.org\/10.1055\/a-1375-9605.","journal-title":"Der Nuklearmediziner"},{"issue":"4","key":"137_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389\u2013427. https:\/\/doi.org\/10.1210\/er.2002-0007 PubMed PMID: 12920149.","journal-title":"Endocr Rev"},{"issue":"6","key":"137_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","volume":"31","author":"JC Reubi","year":"2004","unstructured":"Reubi JC, K\u00f6rner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31(6):803\u201310. 14985869. https:\/\/doi.org\/10.1007\/s00259-004-1476-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"137_CR29","first-page":"1139","volume":"8","author":"JC Reubi","year":"2002","unstructured":"Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer J-C, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, \u03b2-ALA11, PHE13, NLE14]bombesin(6\u201314). Clin Cancer Res. 2002;8(4):1139\u201346.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"137_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.nucmedbio.2013.07.005","volume":"40","author":"S Richter","year":"2013","unstructured":"Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, et al. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol. 2013;40(8):1025\u201334. https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.07.005 PubMed PMID: 23969085.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"137_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/bc034018l","volume":"14","author":"BE Rogers","year":"2003","unstructured":"Rogers BE, Bigott HM, McCarthy DW, Manna DD, Kim J, Sharp TL, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14(4):756\u201363. https:\/\/doi.org\/10.1021\/bc034018l.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"137_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/pap.0000000000000158","volume":"24","author":"I-M Schaefer","year":"2017","unstructured":"Schaefer I-M, Mari\u00f1o-Enr\u00edquez A, Fletcher JA. What is new in gastrointestinal stromal tumor? Adv Anat Pathol. 2017;24(5):259\u201367. https:\/\/doi.org\/10.1097\/pap.0000000000000158.","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"137_CR33","first-page":"691","volume":"46","author":"J Schuhmacher","year":"2005","unstructured":"Schuhmacher J, Zhang H, Doll J, M\u00e4cke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6\u201314) analog. J Nucl Med. 2005;46(4):691\u20139.","journal-title":"J Nucl Med"},{"issue":"8","key":"137_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/s0969-8051(03)00116-1","volume":"30","author":"CJ Smith","year":"2003","unstructured":"Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30(8):861\u20138. https:\/\/doi.org\/10.1016\/s0969-8051(03)00116-1.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"137_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/gcc.22438","volume":"56","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, et al. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2017;56(4):303\u201313. https:\/\/doi.org\/10.1002\/gcc.22438 Epub 2016\/12\/21. PubMed PMID: 27997714; PubMed Central PMCID: PMCPMC5324566.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"137_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41181-017-0025-9","volume":"2","author":"S Todde","year":"2017","unstructured":"Todde S, Peitl PK, Elsinga P, Koziorowski J, Ferrari V, Ocak EM, et al. Guidance on validation and qualification of processes and operations involving radiopharmaceuticals. EJNMMI Radiopharm Chem. 2017;2(1):8. https:\/\/doi.org\/10.1186\/s41181-017-0025-9 Epub 2017\/01\/01. PubMed PMID: 29503849; PubMed Central PMCID: PMC5824699.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"137_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jlcr.3162","volume":"57","author":"IE Valverde","year":"2014","unstructured":"Valverde IE, Huxol E, Mindt TL. Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting. J Label Compd Radiopharm. 2014;57(4):275\u20138. https:\/\/doi.org\/10.1002\/jlcr.3162 PubMed PMID: 24327435.","journal-title":"J Label Compd Radiopharm"},{"issue":"4","key":"137_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"E Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, B\u00fcttner R, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6(4):249\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(05)70097-8.","journal-title":"Lancet Oncol"},{"issue":"18","key":"137_CR39","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1158\/0008-5472.CAN-03-3845","volume":"64","author":"H Zhang","year":"2004","unstructured":"Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting Bombesin receptor-expressing tumors. Cancer Res. 2004;64(18):6707\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3845.","journal-title":"Cancer Res"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-021-00137-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-021-00137-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-021-00137-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T10:16:43Z","timestamp":1625566603000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-021-00137-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1186\/s41181-021-00137-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-446161\/v1","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The application of [<sup>68<\/sup>Ga]Ga-NeoB in patients with GIST was approved by the ethical vote 2014-912\u2009W-MA from 13.01.2015.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data is consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}